Skip to main content

CORRECTION article

Front. Pharmacol., 05 August 2022
Sec. Pharmacogenetics and Pharmacogenomics
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.971316

Corrigendum: Validation of single nucleotide variant assays for human leukocyte antigen haplotypes HLA-B*15:02 and HLA-A*31:01 across diverse ancestral backgrounds

This article is a correction to:

  1. Validation of Single Nucleotide Variant Assays for Human Leukocyte Antigen Haplotypes HLA-B*15:02 and HLA-A*31:01 Across Diverse Ancestral Backgrounds

    1. Read original article
Amanda Buchner,Amanda Buchner1,2Xiuying HuXiuying Hu1Katherine J. Aitchison,, Katherine J. Aitchison1,2,3*
  • 1Department of Psychiatry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
  • 2Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada
  • 3Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada

A Corrigendum on
Validation of single nucleotide variant assays for human leukocyte antigen haplotypes HLA-B*15:02 and HLA-A*31:01 across diverse ancestral backgrounds

by Buchner, A., Hu, X., and Aitchison, K. J. (2021). Front. Pharmacol. 12:713178. doi: 10.3389/fphar.2021.713178

Text Correction.

In the published article, there was an error. Several “rs” numbers were written incorrectly.

A correction has been made to Abstract. This sentence previously stated:

“A custom assay for rs106235 identified HLA-A*31:01 with 100% sensitivity and 95% specificity. The slight reduction in specificity for the latter was owing to another haplotype (HLA-A*33:03) also being detected. While any positive call using the rs106235 assay could therefore be further investigated, as the presence of the HLA-A*31:01 haplotype confers adverse drug reaction risk, the absence of false negatives (indexed by sensitivity) is more important than false positives.”

The corrected sentence appears below:

“A custom assay for rs1061235 identified HLA-A*31:01 with 100% sensitivity and 95% specificity. The slight reduction in specificity for the latter was owing to another haplotype (HLA-A*33:03) also being detected. While any positive call using the rs1061235 assay could therefore be further investigated, as the presence of the HLA-A*31:01 haplotype confers adverse drug reaction risk, the absence of false negatives (indexed by sensitivity) is more important than false positives.”

A correction has been made to Results, TaqMan Assay Analytical Validation, Paragraph 3. This sentence previously stated:

“The assay targeting rs17179220, C__33414939_10, identified HLA-A*31:01 with 100% sensitivity and 100% specificity.”

The corrected sentence appears below:

“The assay targeting rs17179220, C__33415939_10, identified HLA-A*31:01 with 100% sensitivity and 100% specificity.”

A correction has been made to Discussion, Paragraph 4. This sentence previously stated:

“Assay C__33414939_10 for rs17179220 had 100% sensitivity and specificity for HLA-A*31:01.”

The corrected sentence appears below:

“Assay C__33415939_10 for rs17179220 had 100% sensitivity and specificity for HLA-A*31:01.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: HLA antigens, adverse drug reactions, carbamazepine, psychiatry, pharmacogenetics, precision medicine, single nucleotide variants, oxcarbazepine

Citation: Buchner A, Hu X and Aitchison KJ (2022) Corrigendum: Validation of single nucleotide variant assays for human leukocyte antigen haplotypes HLA-B*15:02 and HLA-A*31:01 across diverse ancestral backgrounds. Front. Pharmacol. 13:971316. doi: 10.3389/fphar.2022.971316

Received: 16 June 2022; Accepted: 04 July 2022;
Published: 05 August 2022.

Edited and reviewed by:

Christina Mitropoulou, The Golden Helix Foundation, United Kingdom

Copyright © 2022 Buchner, Hu and Aitchison. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Katherine J. Aitchison, kaitchis@ualberta.ca

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.